Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 235, Issue 1-2, Pages 104-109Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2011.03.011
Keywords
Amyotrophic lateral sclerosis; Complement; Motor neurons; Neuromuscular junction
Categories
Funding
- Wellcome Trust [084542, 068590]
- Medical Research Council [G0700102] Funding Source: researchfish
- MRC [G0700102] Funding Source: UKRI
Ask authors/readers for more resources
Complement activation products are elevated in cerebrospinal fluid, spinal cord and motor cortex of patients with amyotrophic lateral sclerosis (ALS) but are untested in models. We determined complement expression and activation in the SOD1 G93A mouse model of familial ALS (fALS). At 126 days, C3 mRNA was upregulated in spinal cord and C3 protein accumulated in astrocytes and motor neurons. C3 activation products C3b/iC3b were localized exclusively on motor neurons. At the neuromuscular junction, deposits of C3b/iC3b and C1q were detected at day 47, before the appearance of clinical symptoms, and remained detectable at symptomatic stage (126 days). Our findings implicate complement in the denervation of the muscle endplate by day 47 and destruction of the neuromuscular junction and spinal neuron loss by day 126 in the SOD1 G93A mouse model of fALS. (C) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available